Immunovant, Inc. (IMVT) stock
IMVTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
$33.21−0.07 (-0.21%)
Close on Nov 17, 2026Market cap $6.86BP/E –Yield –
Immunovant operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Immunovant's operating cash flow for the twelve months ending Jun 30, 2026 was -$414.30M. For fiscal 2026 it was -$407.31M. The highest annual figure on record is -$28.55M in fiscal 2019.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | -$407.31M | – |
| FY2025 | Mar 31, 2025 | -$375.87M | – |
| FY2024 | Mar 31, 2024 | -$214.23M | – |
| FY2023 | Mar 31, 2023 | -$188.19M | – |
| FY2022 | Mar 31, 2022 | -$106.11M | – |
| FY2021 | Mar 31, 2021 | -$83.33M | – |
| FY2020 | Mar 31, 2020 | -$53.36M | – |
| FY2019 | Mar 31, 2019 | -$28.55M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | -$124.41M | – |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | -$95.06M | – |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | -$92.33M | – |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | -$102.52M | – |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | -$117.41M | – |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | -$110.64M | – |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | -$100.39M | – |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | -$88.65M | – |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | -$76.20M | – |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | -$59.70M | – |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | -$47.10M | – |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | -$60.06M | – |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | -$47.37M | – |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | -$55.79M | – |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | -$46.40M | – |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | -$20.19M | – |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | -$65.82M | – |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | -$32.96M | – |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | -$31.90M | – |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | -$20.05M | – |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | -$21.21M | – |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | -$22.50M | – |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | -$22.82M | – |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | -$24.22M | – |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | -$13.80M | – |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | -$27.47M | – |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | -$8.33M | – |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | -$450 | – |
See a number that looks wrong?